Stay updated with breaking news from Nasdaq Apls. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares fell 3.5% during trading on Monday after Mizuho lowered their price target on the stock from $60.00 to $52.00. Mizuho currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $48.01 and last traded at $48.11. 88,800 shares changed hands during trading, […]
HC Wainwright reaffirmed their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a report released on Friday, Benzinga reports. The firm currently has a $92.00 target price on the stock. Other equities research analysts have also recently issued research reports about the company. UBS Group upped their target price on Apellis […]
Xponance Inc. reduced its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 6.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,927 shares of the company’s stock after selling 939 shares during the quarter. Xponance Inc.’s holdings in Apellis Pharmaceuticals […]
WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference...
Jennison Associates LLC reduced its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 7.5% in the fourth quarter, Holdings Channel reports. The firm owned 3,275,922 shares of the company’s stock after selling 266,287 shares during the period. Jennison Associates LLC’s holdings in Apellis Pharmaceuticals were worth $196,097,000 at the end of […]